Lead Product(s): HST-003
Therapeutic Area: Musculoskeletal Product Name: HST-003
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: U.S. Department of Defense
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding September 16, 2020
The funding supports Phase 1/2 clinical trial of HST-003 for regeneration of cartilage in the knee led by Histogen. The trial is designed to evaluate HST-003 in combination with a microfracture procedure to treat recent focal cartilage defects in the knee caused by injury.